<DOC>
	<DOCNO>NCT02501928</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability fesoterodine follow daily long-term treatment Japanese pediatric neurogenic detrusor overactivity ( NDO ) subject .</brief_summary>
	<brief_title>Open-label Long-term Extension Study Fesoterodine Japanese Subjects With Neurogenic Detrusor Overactivity .</brief_title>
	<detailed_description>This Phase 3 , multi-center , open-label long-term extension study Japanese NDO subject participate complete precedent Study A0221047 24 week , randomize , open label study , investigate safety tolerability fesoterodine . This study consist 28-week open-label treatment period follow 4-week follow-up . In addition , subject oxybutynin arm precedent Study A0221047 continue fesoterodine treatment Week 40 visit study , order obtain fesoterodine 1 year treatment data .</detailed_description>
	<mesh_term>Urinary Bladder , Neurogenic</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>â€¢Subjects complete 24 week treatment visit procedure precedent Study A0221047 Subjects major protocol violation ( determine Sponsor ) Study A0221047 Concomitant medication may increase risk subject confound study result Other medical condition may increase risk subject confound study result</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>neurogenic detrusor overactivity</keyword>
	<keyword>fesoterodine</keyword>
	<keyword>Japan</keyword>
</DOC>